

Clinical And Genetic Spectrum of Myotonia Congenita in Turkish Children

Gökçen ÖZ TUNÇER¹, Aslıhan SANRI², Seren AYDIN¹, Özlem M. HERGÜNER³, Nezir ÖZGÜN⁴, Mustafa KÖMÜR⁵, Dilara F. İÇAĞASIOĞLU⁶, Rabia TÜTÜNCÜ TOKER⁻, Sanem YILMAZ⁶, Elif ACAR ARSLAN⁶, Mesut GÜNGÖR¹⁰, Gültekin KUTLUK¹¹, Şeyda BEŞEN¹², Gülen GÜL MERT³, Burçin GÖNÜLLÜ POLAT⁵, Ayşe AKSOY¹

¹Division of Pediatric Neurology, Department of Pediatrics, Faculty of Medicine, Ondokuz Mayıs University, Samsun, Türkiye

²Department of Pediatric Genetics, University of Health Sciences, Samsun Training and Research Hospital, Samsun, Türkiye

³Division of Pediatric Neurology, Department of Pediatrics, Faculty of Medicine, Çukurova University, Adana, Türkiye

⁴Division of Pediatric Neurology, Department of Pediatrics, Faculty of Medicine, İstinye University, İstanbul, Türkiye

⁵Division of Pediatric Neurology, Department of Pediatrics, Faculty of Medicine, Mersin University, Mersin, Türkiye

⁶Division of Pediatric Neurology, Department of Pediatrics, Faculty of Medicine, Bezmialem Vakıf University, İstanbul, Türkiye

⁷Department of Pediatric Neurology, University of Health Sciences, Bursa City Hospital, Bursa, Türkiye

⁸Division of Pediatric Neurology, Department of Pediatrics, Faculty of Medicine, Ege University, İzmir, Türkiye

⁹Division of Pediatric Neurology, Department of Pediatrics, Faculty of Medicine, Karadeniz Technical University, Trabzon, Türkiye ¹⁰Division of Pediatric Neurology, Department of Pediatrics, Faculty of Medicine, Kocaeli University, Kocaeli, Türkiye ¹¹Department of Pediatric Neurology, University of Health Sciences, Antalya Training and Research Hospital, Antalya, Türkiye ¹²Division of Pediatric Neurology, Department of Pediatrics, Faculty of Medicine, Başkent University, Adana, Türkiye



OBJECTIVES

Myotonia congenita (MC) is the most common form of nondystrophic myotonia and is caused by Mendelian inherited loss-of-function mutations in the *CLCN1* gene encoding the voltage-gated chloride channel of skeletal muscle. These mutations reduce the stabilizing CI– conductance and cause episodes of muscle stiffness. More than 200 pathogenic variants (mostly missense and nonsense) have been identified. But rarely deletions and duplications have also been detected. This study aimed to describe the clinical and genetic spectrum of MC in a large pediatric cohort.

METHODS

Demographic, genetic, and clinical data of the patients younger than 18 years from 11 centers in different geographical regions of Türkiye were retrospectively investigated (Figure I).




Figure I. Distribution of cases by geographical regions of Türkiye

RESULTS

Fifty-three patients (mean age:15.3 years, 75.5% males, with 86.8% Becker, 13.2% Thompsen form) from 34 families were included. Consanguineous marriage rate was 67.9%. 71.7% of patients had a family member with MC. The mean age of disease onset was 5.6 (±4.2) years. 90.6% of the patients described the warm-up phenomenon, 41.5% an increase in complaints by cold. 83% of patients had a hypertrophic appearance. 96.2% grip, 79.2% percussion-activated myotonia were observed. Only myotonia was found in 24 patients who underwent electromyography, and myotonia with

myopathy in 7 patients. Overall 23 different mutations (3/23 were novel) were detected in 51 patients, and large exon deletions were identified in two siblings (Figure II). Most of the mutations were missense and nonsense variants (Figure II). Thomsen and Becker forms were concomitantly observed in one family. Carbamazepine (47.2%), mexiletine (32.1%), phenytoin (3.8%) were preferred for treatment. 66% partial, only 13.2% complete treatment response was observed.

CONCLUSION

This study is the most extended pediatric cohort of turkish individuals until now and will contribute to a better knowledge of the genotypic and phenotypic characteristics of MC patients in Türkiye. The clinical and genetic heterogeneity, as well as the limited response to current treatment options, constitutes an ongoing challenge. In our cohort, recessive MC was more frequent and novel mutations will contribute to the literature.




Figure II. Mutation spectrum of cases